Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in North America, Australia, and internationally. More Details
Undervalued with mediocre balance sheet.
Share Price & News
How has Prestige Consumer Healthcare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PBH has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PBH underperformed the US Pharmaceuticals industry which returned 11.3% over the past year.
Return vs Market: PBH underperformed the US Market which returned 13.8% over the past year.
Price Volatility Vs. Market
How volatile is Prestige Consumer Healthcare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StA Note On Prestige Consumer Healthcare Inc.'s (NYSE:PBH) ROE and Debt To Equity
1 month ago | Simply Wall StAn Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 29% Undervalued
1 month ago | Simply Wall StWhat We Learned About Prestige Consumer Healthcare's (NYSE:PBH) CEO Compensation
Is Prestige Consumer Healthcare undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PBH ($34.55) is trading below our estimate of fair value ($54.02)
Significantly Below Fair Value: PBH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PBH is good value based on its PE Ratio (11.4x) compared to the US Pharmaceuticals industry average (24.3x).
PE vs Market: PBH is good value based on its PE Ratio (11.4x) compared to the US market (17.6x).
Price to Earnings Growth Ratio
PEG Ratio: PBH is poor value based on its PEG Ratio (3x)
Price to Book Ratio
PB vs Industry: PBH is good value based on its PB Ratio (1.4x) compared to the US Pharmaceuticals industry average (2.9x).
How is Prestige Consumer Healthcare forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PBH's forecast earnings growth (3.8% per year) is above the savings rate (2.2%).
Earnings vs Market: PBH's earnings (3.8% per year) are forecast to grow slower than the US market (22.9% per year).
High Growth Earnings: PBH's earnings are forecast to grow, but not significantly.
Revenue vs Market: PBH's revenue (0.5% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: PBH's revenue (0.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PBH's Return on Equity is forecast to be high in 3 years time
How has Prestige Consumer Healthcare performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PBH has high quality earnings.
Growing Profit Margin: PBH became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: PBH's earnings have declined by 3% per year over the past 5 years.
Accelerating Growth: PBH has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: PBH has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: PBH's Return on Equity (12.4%) is considered low.
How is Prestige Consumer Healthcare's financial position?
Financial Position Analysis
Short Term Liabilities: PBH's short term assets ($295.6M) exceed its short term liabilities ($131.9M).
Long Term Liabilities: PBH's short term assets ($295.6M) do not cover its long term liabilities ($2.1B).
Debt to Equity History and Analysis
Debt Level: PBH's debt to equity ratio (132.6%) is considered high.
Reducing Debt: PBH's debt to equity ratio has reduced from 228.3% to 132.6% over the past 5 years.
Debt Coverage: PBH's debt is not well covered by operating cash flow (14.7%).
Interest Coverage: PBH's interest payments on its debt are well covered by EBIT (3.3x coverage).
What is Prestige Consumer Healthcare current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PBH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PBH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PBH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PBH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PBH's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ron Lombardi (56 yo)
Mr. Ronald M. Lombardi, also known as Ron, has been the Chief Executive Officer and President of Prestige Brands Holdings, Inc. (now Prestige Consumer Healthcare Inc.) since June 2015 and has been its Chai ...
CEO Compensation Analysis
Compensation vs Market: Ron's total compensation ($USD5.05M) is about average for companies of similar size in the US market ($USD4.61M).
Compensation vs Earnings: Ron's compensation has been consistent with company performance over the past year.
|Chief Financial Officer||4yrs||US$1.72m||0.073% |
|Senior Vice President of Operations||2.42yrs||US$800.41k||0.023% |
|Senior VP||3.83yrs||US$1.21m||0.042% |
|Executive Vice President of Marketing & Sales||1.33yrs||US$1.12m||no data|
|Director of Investor Relations||no data||no data||no data|
|Director of Communications||no data||no data||no data|
|Senior Vice President of Quality & Regulatory Affairs||2.25yrs||no data||0.015% |
Experienced Management: PBH's management team is considered experienced (3.1 years average tenure).
|Lead Independent Director||11yrs||US$249.52k||0.015% |
|Independent Director||14.67yrs||US$242.02k||0.078% |
|Independent Director||5.33yrs||US$238.90k||0.0084% |
|Independent Director||4.33yrs||US$224.52k||0.0060% |
|Independent Director||1.17yrs||US$185.44k||0.0083% |
|Independent Director||5.08yrs||US$224.52k||0.029% |
Experienced Board: PBH's board of directors are considered experienced (4.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Prestige Consumer Healthcare Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Prestige Consumer Healthcare Inc.
- Ticker: PBH
- Exchange: NYSE
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.734b
- Shares outstanding: 50.19m
- Website: https://www.prestigebrands.com
Number of Employees
- Prestige Consumer Healthcare Inc.
- 660 White Plains Road
- Suite 250
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PBV||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2005|
|PBH||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Feb 2005|
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in North America, Australia, and intern ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/28 06:01|
|End of Day Share Price||2020/09/25 00:00|